High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia
| Autor: | Cunte Chen, Chi Leong Chio, Hui Zeng, Yangqiu Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Poor prognosis Adolescent Gene Expression Bone Marrow Cells Immunophenotyping Transcriptome 03 medical and health sciences Young Adult 0302 clinical medicine hemic and lymphatic diseases Internal medicine Overall survival Biomarkers Tumor Medicine Humans Aged Aged 80 and over business.industry Gene Expression Profiling Myeloid leukemia Bone Marrow Examination Hematology Middle Aged Prognosis Combined Modality Therapy CD56 Antigen Leukemia Myeloid Acute 030220 oncology & carcinogenesis Female Intermediate risk business 030215 immunology |
| Zdroj: | Hematology (Amsterdam, Netherlands). 26(1) |
| ISSN: | 1607-8454 |
| Popis: | Previous study (A total of 262 bone marrow transcriptomic data of IR-AML in the GSE12417-GPL96 and GSE71014-GPL-10558 from the Gene Expression Omnibus database (GEO) database, and 92 IR-AML patients from the cancer genome atlas (TCGA) database were obtained for prognostic analysis and validation.Compared with low CD56 expression, IR-AML patients with high CD56 expression had a longer overall survival (OS) time and restricted mean survival time (RMST) and favorable OS rate in the GSE12417-GPL96 dataset. These results were confirmed in both GSE71014-GPL-10558 and TCGA datasets. Importantly, the inconsistency between our findings and the previous finding may be due to the following reasons: different detection methods, age stratification, countries, treatment options etc.The prognostic value of CD56 expression in IR-AML may need to be comprehensively evaluated based on different detection methods, age stratification, countries, treatment options, and other factors. If confirmed, CD56 may be a biomarker for further risk stratification for IR-AML patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|